Abstract：
While receptor tyrosine kinase-like orphan receptor 1 (ROR1) is typically expressed at low levels or absent in normal tissues, its expression is notably elevated in various malignant tumors and conditions, including chronic lymphocytic leukemia (CLL), breast cancer, ovarian cancer, melanoma, and lung adenocarcinoma. This distinctive feature positions ROR1 as an attractive target for tumor-specific treatments. Currently, several targeted drugs directed at ROR1 are undergoing clinical development, including monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell therapy (CAR-T). Additionally, there are four small molecule inhibitors designed to bind to ROR1, presenting promising avenues for the development of PROTAC degraders targeting ROR1. This review offers updated insights into ROR1\'s structural and functional characteristics, embryonic development implications, cell survival signaling pathways, and evolutionary targeting strategies, all of which have the potential to advance the treatment of malignant tumors.
摘要：
而受体酪氨酸激酶样孤儿受体1（ROR1）通常在正常组织中低水平表达或不存在，它的表达在各种恶性肿瘤和病症中显著升高，包括慢性淋巴细胞白血病（CLL），乳腺癌,卵巢癌,黑色素瘤，和肺腺癌。这一显著特征将ROR1定位为肿瘤特异性治疗的有吸引力的靶标。目前,几种针对ROR1的靶向药物正在进行临床开发，包括单克隆抗体,抗体-药物偶联物（ADC），和嵌合抗原受体T细胞疗法（CAR-T）。此外,有四种小分子抑制剂被设计为与ROR1结合,为开发靶向ROR1的PROTAC降解剂提供了有希望的途径。这篇综述提供了对ROR1结构和功能特征的最新见解，胚胎发育的影响，细胞存活信号通路，和进化目标策略，所有这些都有可能推进恶性肿瘤的治疗。
